Therapeutic Targeting of Cancer Cell Metabolism: Role of Metabolic Enzymes, Oncogenes and Tumor Suppressor GenesRabiya Majeed#, Abid Hamid#*, Yasrib Qurishi, Asif Khurshid Qazi, Aashiq Hussain, Mudassier Ahmed, Rauf Ahmad Najar, Javeed Ahmad Bhat, Shashank Kumar Singh and Ajit Kumar Saxena
Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu 180001, India
- *Corresponding Author:
- Abid Hamid
Cancer Pharmacology Division
Indian Institute of Integrative Medicine
Council of Scientific and Industrial Research
Canal Road, Jammu 180001, India
Tel: +91-191-2569001, Extn: 352
E-mail: [email protected]
Received date: July 13, 2012; Accepted date: August 13, 2012; Published date: August 15, 2012
Citation: Majeed R, Hamid A, Qurishi Y, Qazi AK, Hussain A, et al. (2012) Therapeutic Targeting of Cancer Cell Metabolism: Role of Metabolic Enzymes, Oncogenes and Tumor Suppressor Genes. J Cancer Sci Ther 4:281-291. doi:10.4172/1948-5956.1000156
Copyright: © 2012 Majeed R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Cancer cells compared to their normal counterparts reveal different metabolic needs and this differential requirement of metabolic intermediates and their subsequent consequences require an elaborate understanding of cancer cell metabolism and increased energy production in these cells. Nevertheless these metabolic differences have provided opportunities for developing novel therapeutic approaches for the cancer diagnosis and treatment. In addition enhanced proliferative capacities of tumor cells associated with aberrations of many signal transduction pathways resulting from genetic or epigenetic alterations has made it possible to develop countless targeted therapeutics for several types of malignancies. However at present most of our understanding about the dysregulated cancer cell metabolism is at physiological stages. With advancement in technology development, we may eventually be able to differentiate the metabolic differences between normal cells and cancerous at the single-tumor level that may influence the development of personalized cancer medicine. In this review, the focal point will be the recent developments in understanding the crucial role of metabolic enzymes, oncogenes and tumor suppressor genes in progression of cancer and their targeting to establish the most appropriate therapeutic strategies for better clinical outcome.